Physician profile

Brad Pfeffer

Cardiovascular Disease · Eldersburg, MD

NPI 1255570842

$9,448.69

in general payments reported to CMS, 2019-2025

39 companies · $1,548 in 2025

The $1,548 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,544.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $1,926.43 2019-2025 Xience Skypoint, Dragonfly Opstar, Nc Trek Neo
Medtronic, INC. $1,123.63 2022-2025 Corevalve Evolut R, Micra, Symplicity G3
Novartis Pharmaceuticals Corporation $1,067.36 2019-2025
Edwards Lifesciences Corporation $715.96 2019-2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Boston Scientific Corporation $608.28 2019-2025 Synergy, Avvigo Guidance System
Inari Medical, INC. $430.71 2023-2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Merck Sharp & Dohme LLC $385.10 2021-2025 Verquvo, Capvaxive
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $384.69 2021-2025 Lifevest
Pfizer INC. $237.63 2022-2025
Medtronic Vascular, INC. $211.86 2019
Janssen Pharmaceuticals, INC $193.40 2019-2024 Xarelto
Kestra Medical Technology Services, INC. $152.51 2023-2025 Assure Wcd
Shockwave Medical, INC $147.99 2022
Novo Nordisk INC $144.40 2024-2025 Wegovy, Ozempic
Esperion Therapeutics, INC. $135.09 2021-2024 Nexletol
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $134.11 2023-2025 Amvuttra, Onpattro
Abiomed $131.95 2022-2024 Impella
Scpharmaceuticals INC. $128.33 2024-2025
Amarin Pharma, INC. $112.42 2020-2022
Stryker Corporation $102.95 2025 Flowtriever
Boehringer Ingelheim Pharmaceuticals, INC. $100.36 2021-2025 Jardiance
E.R. Squibb & Sons, L.L.C. $97.36 2022-2025 Camzyos, Eliquis
Irhythm Technologies, INC. $93.98 2021-2024 Zio Xt Patch, Zio Monitor
Philips North America LLC $91.58 2020-2025 Ambulatory Monitoring & Diagnostics Undivided
Amgen INC. $78.34 2021-2022
Astrazeneca Pharmaceuticals LP $71.20 2022-2025 Farxiga
Kiniksa Pharmaceuticals International, Plc $66.56 2024 Arcalyst
Abbvie INC. $61.72 2024-2025
Bayer Healthcare Pharmaceuticals INC. $56.92 2025
Chiesi USA, INC. $53.52 2019-2021
Teleflex LLC $41.87 2023 Guideliner
Lantheus Medical Imaging, INC. $39.04 2019
Cardiva Medical, INC. $22.92 2024 Cardiva Vascade Mvp Vvcs 6-12f
Lexicon Pharmaceuticals, INC. $21.27 2023 Inpefa
Glaxosmithkline, LLC. $17.43 2025 Arexvy, Shingrix
Atricure, INC. $16.10 2023
Terumo Medical Corporation $15.78 2024 Tr Band
Biotronik INC. $14.48 2022
Cardinal Health 200 LLC $13.46 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brad Pfeffer

$9,448.69

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,548 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/1383919/brad-pfeffer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.